Prevail Therapeutics, an early stage biotech developing gene therapies for neurodegenerative diseases, raised $125 million by offering 7.4 million shares at $17, the midpoint of the $16 to $18 range. Prevail Therapeutics plans to list on the Nasdaq under the symbol PRVL. Morgan Stanley, BofA Merrill Lynch and Cowen acted as lead managers on the deal.
